<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1707233877
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MYORA 500 MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MYCOPHENOLATE MOFETIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        194.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Arab Pharmaceutical Manufacturing PSC (Sahab) Co Ltd " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Arab Pharmaceutical Manufacturing PSC (Sahab) Co Ltd 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)	
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Myora contains mycophenolate mofetil.</p><ul><li>This belongs to a group of medicines called &ldquo;immunosuppressants&rdquo;.</li></ul><p>Myora is used to prevent your body rejecting a transplanted organ.</p><ul><li>A kidney, heart or liver.</li></ul><p>Myora should be used together with other medicines:</p><ul><li>Ciclosporin and corticosteroids.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Warning</strong><br />Mycophenolate causes birth defects and miscarriage. If you are a woman who could become pregnant, you must provide a negative pregnancy test before starting treatment and must follow the contraception advice given to you by your doctor.</p><p>Your doctor will speak to you and give you written information, particularly on the effects of mycophenolate on unborn babies. Read the information carefully and follow the instructions.</p><p>If you do not fully understand these instructions, please ask your doctor to explain them again before you take mycophenolate. See also further information in this section under &ldquo;Warnings and precautions&rdquo; and &ldquo;Pregnancy and breast-feeding&rdquo;.</p><p><strong>&nbsp;Do not take Myora</strong></p><ul><li>If you are allergic to mycophenolate mofetil, mycophenolic acid or any of the other ingredients in this medicine (listed in section 6)</li><li>If you are a woman who could be pregnant and you have not provided a negative pregnancy test before your first prescription, as mycophenolate causes birth defects and miscarriage</li><li>If you are pregnant or planning to become pregnant or think you may be pregnant</li><li>If you are not using effective contraception (see Pregnancy, contraception and breast-feeding)</li><li>If you are breast-feeding.</li></ul><p>Do not take this medicine if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking Myora.</p><p><strong>Warnings and precautions</strong><br />Talk to your doctor straight away before starting treatment with Myora:</p><ul><li>If you are older than 65 years as you may have an increased risk of developing adverse events such as certain viral infections, gastrointestinal bleeding and pulmonary oedema when compared to younger patients</li><li>If you have a sign of infection such as a fever or sore throat</li><li>If you have any unexpected bruising or bleeding</li><li>If you have ever had a problem with your digestive system such as a stomach ulcer</li><li>If you are planning to become pregnant or if you get pregnant while you or partner are taking Myora</li><li>If you have a hereditary enzyme deficiency such as Lesch-Nyhan and Kelley-Seegmiller syndrome.</li></ul><p>If any of the above apply to you (or you are not sure), talk to your doctor straight away before starting treatment with Myora.</p><p><strong>The effect of sunlight</strong><br />Mycophenolate reduces your body&rsquo;s defences. As a result, there is an increased risk of skin cancer. Limit the amount of sunlight and UV light you get. Do this by:</p><ul><li>Wearing protective clothing that also covers your head, neck, arms and legs</li><li>Using a sunscreen with a high protection factor.</li></ul><p><strong>Children</strong><br />Do not give this medicine to children younger than 2 years because based on the limited safety and efficacy data for this age group no dose recommendations can be made.</p><p><strong>Other medicines and Myora</strong><br />Tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes medicines obtained without a prescription, such as herbal medicines. This is because Myora can affect the way some other medicines work. Also other medicines can affect the way Myora works.</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines before you start Myora:</p><ul><li>Azathioprine or other medicines that suppress your immune system &ndash; given after a transplant operation</li><li>Cholestyramine &ndash; used to treat high cholesterol</li><li>Rifampicin &ndash; an antibiotic used to prevent and treat infections such as tuberculosis (TB)</li><li>Antacids or proton pump inhibitors &ndash; used for acid problems in your stomach such as indigestion</li><li>Phosphate binders &ndash; used by people with chronic kidney failure to reduce how much phosphate gets absorbed into their blood</li><li>Antibiotics &ndash; used to treat bacterial infections</li><li>Isavuconazole &ndash; used to treat fungal infections</li><li>Telmisartan &ndash; used to treat high blood pressure.</li></ul><p><strong>Vaccines</strong><br />If you need to have a vaccination (a live vaccine) while taking Myora, talk to your doctor or pharmacist first. Your doctor will have to advise you on what vaccines you can have.</p><p>You must not donate blood during treatment with Myora and for at least 6 weeks after stopping treatment. Men must not donate semen during treatment with Myora and for at least 90 days after stopping treatment.</p><p><strong>Myora with food and drink</strong><br />Taking food and drink has no effect on your treatment with mycophenolate.</p><p><strong><em>Pregnancy, contraception and breast-feeding</em><br />Contraception in women taking Myora</strong><br />If you are a woman who could become pregnant, you must use an effective method of contraception with Myora. This includes:</p><ul><li>Before you start taking Myora</li><li>During your entire treatment with Myora</li><li>For 6 weeks after you stop taking Myora.</li></ul><p>Talk to your doctor about the most suitable contraception for you. This will depend on your individual situation. Two forms of contraception are preferable as this will reduce the risk of unintended pregnancy. Contact your doctor as soon as possible, if you think your contraception may not have been effective or if you have forgotten to take your contraceptive pill.</p><p>You cannot become pregnant if any of the following conditions applies to you:</p><ul><li>You are post-menopausal, i.e. at least 50 years old and your last period was more than a year ago (if your periods have stopped because you have had treatment for cancer, then there is still a chance you could become pregnant)</li><li>Your fallopian tubes and both ovaries have been removed by surgery (bilateral salpingo-oophorectomy)</li><li>Your womb (uterus) has been removed by surgery (hysterectomy)</li><li>Your ovaries no longer work (premature ovarian failure, which has been confirmed by a specialist gynaecologist)</li><li>You were born with one of the following rare conditions that make pregnancy impossible: the XY genotype, Turner&rsquo;s syndrome or uterine agenesis</li><li>You are a child or teenager who has not started having periods.</li></ul><p><strong>Contraception in men taking Myora</strong><br />The available evidence does not indicate an increased risk of malformations or miscarriage if the father takes mycophenolate. However, a risk cannot be completely excluded. As a precaution you or your female partner are recommended to use reliable contraception during treatment and for 90 days after you stop taking Myora.</p><p>If you are planning to have a child, talk to your doctor about the potential risks and alternative therapies.</p><p><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor will talk to you about the risks in case of pregnancy and the alternatives you can take to prevent rejection of your transplant organ if:</p><ul><li>You plan to become pregnant</li><li>You miss or think you have missed a period, or you have unusual menstrual bleeding, or suspect you are pregnant</li><li>You have sex without using effective methods of contraception.</li></ul><p>If you do become pregnant during the treatment with mycophenolate, you must inform your doctor immediately. However, keep taking Myora until you see him or her.</p><p><em>Pregnancy</em><br />Mycophenolate causes a very high frequency of miscarriage (50%) and of severe birth defects (23-27%) in the unborn baby. Birth defects which have been reported include anomalies of ears, of eyes, of face (cleft lip/palate), of development of fingers, of heart, oesophagus (tube that connects the throat with the stomach), kidneys and nervous system (for example spina bifida (where the bones of the spine are not properly developed)). Your baby may be affected by one or more of these.</p><p>If you are a woman who could become pregnant, you must provide a negative pregnancy test before starting treatment and must follow the contraception advice given to you by your doctor. Your doctor may request more than one test to ensure you are not pregnant before starting treatment.</p><p><em>Breast-feeding</em><br />Do not take Myora if you are breast-feeding. This is because small amounts of the medicine can pass into the mother&rsquo;s milk.</p><p><strong>Driving and using machines</strong><br />Mycophenolate has a moderate influence on your ability to drive or use any tools or machines. If you feel drowsy, numb or confused, talk to your doctor or nurse and do not drive or use any tools or machines until you feel better.</p><p><strong>Myora contains sodium</strong><br />Myora contains sodium. Each film-coated tablet of Myora 500 mg Film-coated Tablets contains 6.74 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per film coated tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Myora exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>How much to take</strong><br />The amount you take depends on the type of transplant you have had. The usual doses are shown below. Treatment will continue for as long as you need to prevent rejection of your transplant organ.</p><p><strong>Kidney transplant</strong><br /><em>Adults</em></p><ul><li>The first dose is given within 3 days of the transplant operation</li><li>The daily dose is 4 tablets (2 g of the medicine) taken as 2 separate doses</li><li>Take 2 tablets in the morning and then 2 tablets in the evening.</li></ul><p><em>Children (aged 2 to 18 years)</em></p><ul><li>The dose given will vary depending on the size of the child</li><li>Your doctor will decide the most appropriate dose based on your child&rsquo;s height and weight (body surface area &ndash; measured as square metres or &ldquo;m<sup>2</sup>&rdquo;). The recommended dose is 600 mg/m<sup>2</sup> taken twice a day.</li></ul><p><strong>Heart transplant</strong><br /><em>Adults</em></p><ul><li>The first dose is given within 5 days of the transplant operation</li><li>The daily dose is 6 tablets (3 g of the medicine) taken as 2 separate doses</li><li>Take 3 tablets in the morning and then 3 tablets in the evening.</li></ul><p><em>Children</em></p><ul><li>There is no information for the use of mycophenolate in children with a heart transplant.</li></ul><p><strong>Liver transplant</strong><br /><em>Adults</em></p><ul><li>The first dose of oral Myora will be given to you at least 4 days after the transplant operation and when you are able to swallow oral medicines</li><li>The daily dose is 6 tablets (3 g of the medicine) taken as 2 separate doses</li><li>Take 3 tablets in the morning and then 3 tablets in the evening.</li></ul><p><em>Children</em></p><ul><li>There is no information for the use of mycophenolate in children with a liver transplant.</li></ul><p><strong>Taking the medicine</strong></p><ul><li>Swallow your tablets whole with a glass of water</li><li>Do not break or crush them.</li></ul><p><strong>If you take more Myora than you should</strong><br />If you take more Myora than you should, talk to a doctor or go to a hospital straight away. Also do this if someone else accidentally takes your medicine. Take the medicine pack with you.</p><p><strong>If you forget to take Myora</strong><br />If you forget to take your medicine at any time, take it as soon as you remember. Then continue to take it at the usual times. Do not take a double dose to make up for a missed dose.</p><p><strong>If you stop taking Myora</strong><br />Do not stop taking Myora unless your doctor tells you to. If you stop your treatment you may increase the chance of rejection of your transplanted organ.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, mycophenolate mofetil can cause side effects, although not everybody gets them.</p><p><strong>Talk to a doctor straight away if you notice any of the following serious side effects &ndash; you may need urgent medical treatment:</strong></p><ul><li>You have a sign of infection such as a fever or sore throat</li><li>You have any unexpected bruising or bleeding</li><li>You have a rash, swelling of your face, lips, tongue or throat, with difficulty breathing - you may be having a serious allergic reaction to the medicine (such as anaphylaxis, angioeodema).</li></ul><p><strong>Usual problems</strong><br />Some of the more usual problems are diarrhoea, fewer white cells or red cells in your blood, infection and vomiting. Your doctor will do regular blood tests to check for any changes in:</p><ul><li>The number of your blood cells or signs of infections.</li></ul><p>Children may be more likely than adults to have some side effects. These include diarrhoea, infections, fewer white cells and fewer red cells in the blood.</p><p><strong>Fighting infections</strong><br />Mycophenolate reduces your body&rsquo;s defences. This is to stop you rejecting your transplant. As a result, your body will not be as good as normal at fighting infections. This means you may catch more infections than usual. This includes infections of the brain, skin, mouth, stomach and gut, lungs and urinary system.</p><p><strong>Lymph and skin cancer</strong><br />As can happen in patients taking this type of medicine (immune-suppressants), a very small number of patients on mycophenolate have developed cancer of the lymphoid tissues and skin.</p><p><strong>General unwanted effects</strong><br />You may get general side effects affecting your body as a whole. These include serious allergic reactions (such as anaphylaxis, angioeodema), fever, feeling very tired, difficulty sleeping, pains (such as stomach, chest, joint or muscle), headache, flu symptoms and swelling.</p><p><strong><em>Other unwanted effects may include:</em></strong><br /><strong>Skin problems </strong>such as:</p><ul><li>Acne, cold sores, shingles, skin growth, hair loss, rash, itching.</li></ul><p><strong>Urinary problems</strong> such as:</p><ul><li>Blood in the urine.</li></ul><p><strong>Digestive system and mouth problems</strong> such as:</p><ul><li>Swelling of the gums and mouth ulcers,</li><li>Inflammation of the pancreas, colon or stomach,</li><li>Gastrointestinal disorders including bleeding,</li><li>Liver disorders,</li><li>Diarrhoea, constipation, feeling sick (nausea), indigestion, loss of appetite, flatulence.</li></ul><p><strong>Nervous system problems</strong> such as:</p><ul><li>Feeling dizzy, drowsy or numb,</li><li>Tremor, muscle spasms, convulsions,</li><li>Feeling anxious or depressed, changes in your mood or thoughts.</li></ul><p><strong>Heart and blood vessel problems</strong> such as:</p><ul><li>Change in blood pressure, accelerated heartbeat, widening of blood vessels.</li></ul><p><strong>Lung problems</strong> such as:</p><ul><li>Pneumonia, bronchitis,</li><li>Shortness of breath, cough, which can be due to bronchiectasis (a condition in which the lung airways are abnormally dilated) or pulmonary fibrosis (scarring of the lung). Talk to your doctor if you develop a persistent cough or breathlessness, fluid on the lungs or inside the chest</li><li>Sinus problems.</li></ul><p><strong>Other problems</strong> such as:</p><ul><li>Weight loss, gout, high blood sugar, bleeding, bruising.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from light.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is mycophenolate mofetil.</p><p>Each film-coated tablet of Myora 500 mg Film-coated Tablets contains 500 mg mycophenolate mofetil.</p><p>The other ingredients are povidone, croscarmellose sodium, microcrystalline cellulose, magnesium stearate and Opadry grey.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Myora 500 mg Film-coated Tablets are lavender coloured, capsule-shaped film-coated tablets embossed with “MH6” in aluminum blisters.

Pack size: 50 Film-coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Manufacturer</strong><br />The Arab Pharmaceutical Manufacturing PSC<br />Sahab<br />Industrial City<br />P.O. Box 41<br />Amman 11512, Jordan<br />Tel: + (962-6) 4023916<br />Fax: + (962-6) 4023917</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
This leaflet was last revised in 08/2024; version number SA3.0.

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي مايورا على ميكوفينوليت موفيتيل.</p><ul dir="rtl"><li>وينتمي إلى مجموعة الأدوية التي تُسمى &quot;كابتات المناعة&quot;.</li></ul><p dir="RTL">يستخدم مايورا لمنع جسمك من رفض عضو مزروع.</p><ul dir="rtl"><li>كلية، القلب أو الكبد.</li></ul><p dir="RTL">يجب استخدام مايورا مع أدوية أخرى:</p><ul dir="rtl"><li>سيكلوسبورين والستيرويدات القشرية.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تحذير&nbsp;</strong><br />يتسبب ميكوفينوليت في حدوث العيوب الخلقية والإجهاض. إذا كنتِ امرأة يمكن أن تصبح حاملاً، فيجب عليكِ تقديم فحص حمل سلبي قبل بدء العلاج ويجب عليكِ اتباع نصائح منع الحمل المقدمة إليكِ من قبل طبيبك.</p><p dir="RTL">سيتحدث معكِ طبيبك ويقدم لك معلومات مكتوبة، خاصة حول تأثيرات ميكوفينوليت على الأجنة. اقرئي المعلومات بعناية واتبعي التعليمات.</p><p dir="RTL">إذا لم تفهمي هذه التعليمات تمامًا، فيرجى أن تطلبي من طبيبك شرحها لكِ مرة أخرى قبل أن تتناولي ميكوفينوليت. انظري أيضًا المعلومات الإضافية في هذا القسم أسفل &quot;الاحتياطات والتحذيرات&quot; و&quot;الحمل والرضاعة&quot;.</p><p dir="RTL"><strong>&nbsp;لا</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>مايورا</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لميكوفينوليت موفيتيل، حمض الميكوفينوليك أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6)</li><li>إذا كنتِ امرأة يمكن أن تكوني حاملاً ولم تقومي بتقديم فحص حمل سلبي قبل أول وصفة لكِ، حيث إن ميكوفينوليت يتسبب في حدوث عيوب خلقية وإجهاض</li><li>إذا كنتِ حاملًا أو تخططين للحمل أو تعتقدين أنك حاملًا</li><li>إذا كنت لا تستخدمين وسيلة فعالة لمنع الحمل (انظري إلى الحمل، وسائل منع الحمل والرضاعة)</li><li>إذا كنتِ مُرضع.</li></ul><p dir="RTL">لا تتناول هذا الدواء إذا كان ينطبق عليك أي مما ورد أعلاه. إذا لم تكن متأكدًا، فاستشر طبيبك أو الصيدلي قبل تناول مايورا.</p><p dir="RTL"><strong>الاحتياطات<strong> </strong>والتحذيرات&nbsp;</strong><br />تحدث مع طبيبك قبل البدء بالعلاج بمايورا مباشرة:</p><ul dir="rtl"><li>إذا كان عمرك أكثر من 65 عام وذلك لأنك قد تعاني من ارتفاع خطر الإصابة بالأحداث الضائرة مثل حالات عدوى فيروسية معينة، نزيف في الجهاز الهضمي والوذمة الرئوية مقارنة بالمرضى الأصغر&nbsp;</li><li>إذا ظهرت عليك علامة للإصابة بعدوى كالحمى أو احتقان الحلق</li><li>إذا تعرضت لأي كدمات أو نزيف غير متوقع</li><li>إذا سبق وعانيت من مشكلة في الجهاز الهضمي مثل القرحة المعدية</li><li>إذا كنتِ تخططين للحمل أو إذا أصبحتِ حاملاً أثناء تناولكِ أنت أو شريككِ مايورا</li><li>إذا كنت تعاني من نقص كفاءة إنزيم وراثي مثل متلازمة ليش نيهان وكيلي سيغميلر.</li></ul><p dir="RTL">إذا كان ينطبق عليك أي مما سبق (أو إذا لم تكن متأكدًا)، فتحدث مع طبيبك قبل البدء بالعلاج بمايورا مباشرة.</p><p dir="RTL"><strong>تأثير</strong><strong> </strong><strong>أشعة<strong> </strong>الشمس&nbsp;</strong><br />يقلل ميكوفينوليت من مقاومة جسمك. نتيجة لذلك، يكون هناك خطر متزايد للإصابة بسرطان الجلد. قم بالحد من مقدار أشعة الشمس والأشعة فوق البنفسجية التي تتعرض لها. قم بذلك من خلال:</p><ul dir="rtl"><li>ارتداء ملابس واقية التي تغطي أيضًا رأسك، رقبتك، ذراعيك وساقيك</li><li>استخدام كريم واقي من أشعة الشمس ذو عامل حماية مرتفع.</li></ul><p dir="RTL"><strong>الأطفال&nbsp;</strong><br />لا تقم بإعطاء هذا الدواء للأطفال الذين تقل أعمارهم عن سنتين لأنه لا يمكن إعطاء توصيات للجرعات بالاعتماد على معلومات المأمونية والفاعلية المحدودة لهذا العمر.</p><p dir="RTL"><strong>&nbsp;الأدوية</strong><strong> </strong><strong>الأخرى<strong> </strong>ومايورا&nbsp;</strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أية أدوية أخرى. ويشمل ذلك الأدوية التي حصلت عليها بدون وصفة طبية، مثل الأدوية العشبية. ذلك لأن مايورا قد يؤثر على طريقة عمل بعض الأدوية الأخرى. كما يُمكن أن تؤثر الأدوية الأخرى على طريقة عمل مايورا.</p><p dir="RTL">على وجه الخصوص، أبلغ طبيبك أو الصيدلي إذا كنت تتناول أيًّا من الأدوية التالية قبل البدء في تناول مايورا:</p><ul dir="rtl"><li>أزاثيوبرين أو الأدوية الأخرى التي تثبط جهازك المناعي - التي تُعطى بعد إجراء عملية زراعة عضو</li><li>كولستيرامين - يُستخدم لعلاج ارتفاع الكوليسترول</li><li>ريفامبيسين - مضاد حيوي يُستخدم للوقاية من وعلاج حالات العدوى مثل السل</li><li>مضادات الحموضة أو مثبطات مضخة البروتون - تُستخدم لعلاج مشاكل الحموضة في المعدة مثل عسر الهضم</li><li>رابطات الفوسفات - تُستخدم من قبل الأشخاص الذي يعانون من فشل كلوي مزمن لتقليل كمية الفوسفات التي يتم امتصاصها في الدم لديهم</li><li>المضادات الحيوية - تُستخدم لعلاج العدوى البكتيرية</li><li>إيزافوكونازول - يُستخدم لعلاج العدوى الفطرية</li><li>تلميسارتان - يُستخدم لعلاج ارتفاع ضغط الدم.</li></ul><p dir="RTL"><strong>اللقاحات&nbsp;</strong><br />إذا كنت بحاجة للحصول على لقاح (لقاح حي) أثناء تناول مايورا، فاستشر طبيبك أو الصيدلي أولاً. سيتعين على طبيبك تقديم المشورة لك بشأن اللقاحات التي يمكنك الحصول عليها.</p><p dir="RTL">يجب عليك عدم التبرع بالدم أثناء العلاج باستخدام مايورا ولمدة 6 أسابيع على الأقل بعد إيقاف العلاج. يجب على الرجال عدم التبرع بالسائل المنوي أثناء العلاج باستخدام مايورا ولمدة 90 يومًا على الأقل بعد إيقاف العلاج.</p><p dir="RTL"><strong>مايورا</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الطعام<strong> </strong>والشراب&nbsp;</strong><br />تناول الطعام والشراب ليس له تأثير على علاجك باستخدام ميكوفينوليت.</p><p dir="RTL"><strong><em>الحمل</em></strong><strong><em>، </em></strong><strong><em>وسائل</em></strong><strong><em> </em></strong><strong><em>منع</em></strong><strong><em> </em></strong><strong><em>الحمل</em></strong><strong><em> </em></strong><strong><em>والرضاعة&nbsp;</em></strong><br /><strong>منع</strong><strong> </strong><strong>الحمل</strong><strong> </strong><strong>في</strong><strong> </strong><strong>النساء</strong><strong> </strong><strong>اللاتي</strong><strong> </strong><strong>يتناولن<strong> </strong>مايورا&nbsp;</strong><br />إذا كنتِ امرأة قد تصبحين حاملاً، فيجب عليكِ استخدام وسيلة فعالة لمنع الحمل مع مايورا. تشمل هذه الوسائل:</p><ul dir="rtl"><li>قبل البدء في تناول مايورا</li><li>أثناء فترة علاجك بالكامل باستخدام مايورا</li><li>لمدة 6 أسابيع بعد توقفك عن تناول مايورا.</li></ul><p dir="RTL">استشيري طبيبك حول أكثر وسيلة مناسبة لكِ لمنع الحمل. سيعتمد ذلك على حالتك الفردية. يفضل استخدام وسيلتين لمنع الحمل لأن ذلك يقلل من خطر حدوث حمل غير مقصود. تواصلي مع طبيبك في أقرب وقت ممكن، إذا كنتِ تعتقدين أن وسيلة منع الحمل الخاصة بكِ لم تكن فعالة أو في حالة نسيانك تناول حبة منع الحمل الخاصة بكِ.</p><p dir="RTL">تكوني امرأة غير قادرة على الحمل إذا كان ينطبق عليكِ أي مما يلي:</p><ul dir="rtl"><li>كنتِ في فترة ما بعد انقطاع الطمث، أي تبلغين 50 عامًا على الأقل ومر على آخر دورة طمث لكِ أكثر من عام (إذا توقفت دورات الطمث لديكِ لأنك خضعت لعلاج للسرطان، فلا تزال لديكِ فرصة في الحمل)</li><li>تم إزالة قناتي فالوب وكلا المبيضين لديكِ جراحيًا (استئصال بوقي مبيضي ثنائي الجانب)</li><li>تم إزالة رحمك جراحيًا (استئصال الرحم)</li><li>لم يعد المبيضان لديكِ يعملان (الفشل المبكر للمبيض، والذي تم تأكيده بواسطة أخصائي أمراض نسائية)</li><li>ولدتِ بأحد الحالات النادرة التالية التي تجعل الحمل مستحيلاً: النمط الجيني XY، متلازمة تيرنر أو عدم التخلق الرحمي</li><li>كنتِ طفلة أو مراهقة لم تبدأ دورات الطمث لديها.</li></ul><p dir="RTL"><strong>وسائل</strong><strong> </strong><strong>العزل</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الرجال</strong><strong> </strong><strong>الذين</strong><strong> </strong><strong>يتناولون<strong> </strong>مايورا&nbsp;</strong><br />لا تشير الأدلة المتاحة إلى زيادة خطر حدوث التشوهات الخلقية أو الإجهاض إذا كان الأب يتناول ميكوفينوليت. مع ذلك، لا يمكن استبعاد الخطر تمامًا. كإجراء احتياطي يوصى أن تستخدم أنت وشريكتك وسيلة موثوقة لمنع الحمل أثناء العلاج ولمدة 90 يومًا بعد توقفك عن تناول مايورا.</p><p dir="RTL">إذا كنت تخطط لإنجاب طفل، تحدث إلى طبيبك حول المخاطر المحتملة والعلاجات البديلة.</p><p dir="RTL"><strong>الحمل<strong> </strong>والرضاعة&nbsp;</strong><br />استشيري طبيبك أو الصيدلي، إذا كنتِ حاملاً أو مرضعًا، تعتقدين بأنك حاملاً أو تخططين لذلك. سيتحدث معك طبيبك حول المخاطر في حالة الحمل والبدائل التي يمكنك تناولها للوقاية من رفض العضو المزروع لديك في الحالات التالية:</p><ul dir="rtl"><li>كنتِ تخططين للحمل</li><li>فاتتك دورة طمث أو اعتقدتِ ذلك، أو تعرضتِ لنزيف حيضي غير معتاد، أو شككتِ أنك حامل</li><li>مارستِ الجنس بدون استخدام وسيلة فعالة لمنع الحمل.</li></ul><p dir="RTL">إذا أصبحت حاملاً أثناء العلاج باستخدام ميكوفينوليت، فيجب عليكِ إبلاغ طبيبك فورًا. مع ذلك، استمري في تناول مايورا حتى تقومي بزيارته أو زيارتها.</p><p dir="RTL"><em>الحمل&nbsp;</em><br />يتسبب ميكوفينوليت في زيادة معدل تكرار حدوث الإجهاض (50%) وعيوب خلقية خطيرة (23-27%) في الجنين. تشمل العيوب الخلقية التي تم الإبلاغ عنها عيوب الأذنين، العينين، الوجه (الشفة/الحنك المشقوق)، عيوب في نمو الأصابع، القلب، المريء (القناة التي تصل الحلق بالمعدة)، عيوب الكلى والجهاز العصبي (مثل السنسنة المشقوقة (حيث لا تنمو عظام العمود الفقري بشكل صحيح)). قد يتأثر طفلك بواحدة أو أكثر من هذه الحالات.</p><p dir="RTL">إذا كنتِ امرأة قد تصبحين حاملاً، فيجب عليكِ تقديم فحص حمل سلبي قبل بدء العلاج ويجب عليكِ اتباع نصائح منع الحمل المقدمة من طبيبك. قد يطلب طبيبك إجراء أكثر من فحص واحد للتأكد من أنكِ لستِ حاملاً قبل بدء العلاج.</p><p dir="RTL"><em>الرضاعة&nbsp;</em><br />لا تتناولي مايورا إذا كنتِ مرضعًا. ذلك لأن هناك كميات صغيرة من الدواء قد تصل إلى حليب الأم.</p><p dir="RTL">&nbsp;<strong>القيادة</strong><strong> </strong><strong>واستخدام<strong> </strong>الآلات&nbsp;</strong><br />لميكوفينوليت تأثير متوسط على قدرتك على القيادة أو استخدام أي أدوات أو آلات. إذا كنت تشعر بالنعاس، الخدران أو الارتباك، تحدث إلى طبيبك أو الممرض ولا تقم بالقيادة أو استخدام أي أدوات أو آلات حتى تشعر بالتحسن.</p><p dir="RTL"><strong>يحتوي مايورا على الصوديوم&nbsp;</strong><br />يحتوي مايورا على الصوديوم. يحتوي كل قرص مغطى بطبقة رقيقة من مايورا 500 ملغم أقراص مغطاة بطبقة رقيقة على 6,74 ملغم صوديوم. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل قرص مغطى بطبقة رقيقة، وبذلك يمكن اعتباره &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائمًا بتناول مايورا كما وصفه لك طبيبك. تحقق من طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL"><strong>الجرعة<strong> </strong>التي يجب تناولها&nbsp;</strong><br />تعتمد الكمية التي تتناولها على نوع عملية الزرع التي خضعت لها. الجرعات المعتادة موضحة أدناه. سيستمر العلاج طوال الفترة التي تحتاجها لمنع رفض العضو المزروع لديك.</p><p dir="RTL"><strong>زراعة<strong> </strong>الكلى&nbsp;</strong><br /><em>البالغون</em></p><ul dir="rtl"><li>يتم إعطاء الجرعة الأولى خلال 3 أيام من عملية الزراعة</li><li>تبلغ الجرعة اليومية 4 أقراص (2 غم من الدواء) يتم تناولها كجرعتين منفصلتين</li><li>تناول قرصين في الصباح وثم قرصين في المساء.</li></ul><p dir="RTL"><em>الأطفال</em><em> (</em><em>الذين</em><em> </em><em>تتراوح</em><em> </em><em>أعمارهم</em><em> </em><em>من</em><em> </em><em>عامين</em><em> </em><em>إلى</em><em> 18 </em><em>عامًا</em><em>)</em></p><ul dir="rtl"><li>ستختلف الجرعة المعطاة تبعًا لحجم الطفل</li><li>سيقرر طبيبك الجرعة الأكثر ملائمة بناءً على طول ووزن طفلك (مساحة سطح الجسم - مقاسة بالمتر المربع أو &quot;م<sup>2</sup>&quot;). الجرعة الموصى بها هي 600 ملغم/م<sup>2</sup> يتم تناولها مرتين في اليوم.</li></ul><p dir="RTL"><strong>زراعة<strong> </strong>القلب&nbsp;</strong><br /><em>البالغون</em></p><ul dir="rtl"><li>يتم إعطاء الجرعة الأولى خلال 5 أيام من عملية الزراعة</li><li>تبلغ الجرعة اليومية 6 أقراص (3 غم من الدواء) يتم تناولها كجرعتين منفصلتين</li><li>تناول 3 أقراص في الصباح وثم 3 أقراص في المساء.</li></ul><p dir="RTL"><em>الأطفال</em></p><ul dir="rtl"><li>لا توجد معلومات حول استخدام ميكوفينوليت في الأطفال الذين خضعوا لزراعة قلب.</li></ul><p dir="RTL"><strong>زراعة<strong> </strong>الكبد&nbsp;</strong><br /><em>البالغون</em></p><ul dir="rtl"><li>سيتم إعطاؤك الجرعة الأولى من مايورا الفموي بعد 4 أيام على الأقل من عملية الزراعة وعندما تكون قادرًا على ابتلاع الأدوية الفموية</li><li>تبلغ الجرعة اليومية 6 أقراص (3 غم من الدواء) يتم تناولها كجرعتين منفصلتين</li><li>تناول 3 أقراص في الصباح و3 أقراص في المساء.</li></ul><p dir="RTL"><em>الأطفال</em></p><ul dir="rtl"><li>لا توجد معلومات حول استخدام ميكوفينوليت في الأطفال الذين خضعوا لزراعة كبد.</li></ul><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>الدواء</strong></p><ul dir="rtl"><li>ابلع أقراصك كاملة مع شرب كوب من الماء</li><li>لا تكسر أو تسحق الأقراص.</li></ul><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>زائدة</strong><strong> </strong><strong>من<strong> </strong>مايورا&nbsp;</strong><br />إذا تناولت جرعات زائدة من مايورا، فتحدث مع طبيب أو توجه إلى المستشفى على الفور. قم بذلك أيضًا إذا تناول شخص آخر الدواء الخاص بك عن غير قصد. وخذ عبوة الدواء معك.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>تناول<strong> </strong>مايورا&nbsp;</strong><br />إذا نسيت تناول دوائك في أي وقت، تناوله فور تذكره. ثم استمر في تناوله في الأوقات المعتادة. لا تقم بتناول جرعة مضاعفة لتعويض جرعة منسية.</p><p dir="RTL"><strong>إذا</strong><strong> </strong><strong>توقفت</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول<strong> </strong>مايورا&nbsp;</strong><br />لا تتوقف عن تناول مايورا إلا إذا أخبرك طبيبك بذلك. إذا قمت بإيقاف علاجك فقد تزيد من خطر رفض العضو المزروع لديك.</p><p dir="RTL">إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، فاستشر طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب ميكوفينوليت موفيتيل آثارًا جانبية، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><strong>استشر</strong><strong> </strong><strong>طبيبًا</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الفور</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>لاحظت</strong><strong> </strong><strong>أيًا</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الآثار</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>الخطيرة</strong><strong> </strong><strong>التالية</strong><strong> - </strong><strong>لأنك</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>تحتاج</strong><strong> </strong><strong>إلى</strong><strong> </strong><strong>علاج</strong><strong> </strong><strong>طبي</strong><strong> </strong><strong>عاجل:</strong></p><ul dir="rtl"><li>إذا ظهرت عليك علامة للإصابة بعدوى كالحمى أو احتقان الحلق</li><li>إذا تعرضت لأي كدمات أو نزيف غير متوقع</li><li>إذا عانيت من طفح جلدي، تورم الوجه، الشفتين، اللسان أو الحلق، مع وجود صعوبة في التنفس - فقد تكون مصابًا برد فعل تحسسي خطير اتجاه الدواء (مثل التأق، الوذمة الوعائية).</li></ul><p dir="RTL"><strong>المشاكل<strong> </strong>المعتادة&nbsp;</strong><br />بعض من المشكلات الأكثر تكرارًا هي الإسهال، انخفاض عدد خلايا الدم البيضاء أو الحمراء في الدم، العدوى والقيء. سيقوم طبيبك بإجراء فحوصات الدم المنتظمة للتحقق من أي تغيرات في:</p><ul dir="rtl"><li>عدد خلايا الدم لديك أو علامات العدوى.</li></ul><p dir="RTL">قد يكون الأطفال أكثر عرضة من البالغين في الإصابة ببعض الآثار الجانبية. وتشمل الإسهال، العدوى، انخفاض عدد خلايا الدم البيضاء والحمراء في الدم.</p><p dir="RTL"><strong>مكافحة<strong> </strong>العدوى&nbsp;</strong><br />يقلل ميكوفينوليت من مقاومة جسمك. وذلك لإيقاف رفض جسمك للعضو المزروع. نتيجة لذلك، لن يكون جسمك بحالة جيدة بالشكل الطبيعي في مكافحة العدوى. يعني ذلك أنك قد تصاب بمزيد من حالات العدوى عن المعتاد. يشمل ذلك عدوى الدماغ، الجلد، الفم، المعدة والأمعاء، الرئتين والجهاز البولي.</p><p dir="RTL"><strong>سرطان</strong><strong> </strong><strong>الغدد</strong><strong> </strong><strong>الليمفاوية<strong> </strong>والجلد&nbsp;</strong><br />نظرًا لإمكان حدوث ذلك في المرضى الذين يتناولون هذا النوع من الأدوية (كابتات المناعة)، أصيب عدد صغير جدًا من المرضى الذين يتناولون ميكوفينوليت بسرطان الأنسجة الليمفاوية والجلد.</p><p dir="RTL"><strong>الآثار</strong><strong> </strong><strong>العامة غير<strong> </strong>المرغوبة&nbsp;</strong><br />قد تعاني من آثار جانبية عامة تؤثر على جسمك بالكامل. تشمل هذه الآثار ردود الفعل التحسسية الخطيرة (مثل التأق، الوذمة الوعائية)، الحمى، &nbsp;الشعور بالتعب الشديد، صعوبة في النوم، الآلام (مثل ألم في المعدة، الصدر، المفاصل أو العضلات)، الصداع، أعراض الأنفلونزا والتورم.</p><p dir="RTL"><strong><em>قد</em></strong><strong><em> </em></strong><strong><em>تشمل</em></strong><strong><em> </em></strong><strong><em>الآثار</em></strong><strong><em> </em></strong><strong><em>غير</em></strong><strong><em> </em></strong><strong><em>المرغوبة</em></strong><strong><em> </em></strong><strong><em>الأخرى</em></strong><strong><em>:&nbsp;</em></strong><br /><strong>مشاكل</strong><strong> </strong><strong>جلدية</strong><strong> </strong>مثل:</p><ul dir="rtl"><li>حب الشباب، قرح الزكام، الهربس النطاقيّ، نمو في الجلد، تساقط الشعر، طفح جلدي، حكة.</li></ul><p dir="RTL"><strong>مشاكل</strong><strong> </strong><strong>في</strong><strong> </strong><strong>المسالك</strong><strong> </strong><strong>البولية</strong> مثل:</p><ul dir="rtl"><li>دم في البول.</li></ul><p dir="RTL"><strong>مشاكل</strong><strong> </strong><strong>الجهاز</strong><strong> </strong><strong>الهضمي</strong><strong> </strong><strong>والفم</strong> مثل:</p><ul dir="rtl"><li>تورم اللثة وتقرح الفم،</li><li>التهاب البنكرياس، القولون أو المعدة،</li><li>اضطرابات الجهاز الهضمي بما في ذلك النزيف،</li><li>اضطرابات في الكبد،</li><li>الإسهال، الإمساك، الشعور بالإعياء (الغثيان)، عسر الهضم، فقدان الشهية، الانتفاخ.</li></ul><p dir="RTL"><strong>مشاكل</strong><strong> </strong><strong>الجهاز</strong><strong> </strong><strong>العصبي</strong> مثل:</p><ul dir="rtl"><li>الشعور بالدوخة، النعاس أو الخدران،</li><li>الرعاش، التشنجات العضلية، الاختلاجات،</li><li>الشعور بالقلق أو الاكتئاب، تغيرات في مزاجك أو أفكارك.</li></ul><p dir="RTL"><strong>مشاكل</strong><strong> </strong><strong>القلب</strong><strong> </strong><strong>والأوعية</strong><strong> </strong><strong>الدموية</strong> مثل:</p><ul dir="rtl"><li>تغير في ضغط الدم، تسارع نبضات قلب، اتساع الأوعية الدموية.</li></ul><p dir="RTL"><strong>مشاكل</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الرئة</strong> مثل:</p><ul dir="rtl"><li>التهاب الرئة، التهاب الشعب الهوائية،</li><li>ضيق النفس، السعال، الذي قد يكون بسبب توسع القصبات (حالة تتوسع فيها المسالك الهوائية للرئة بشكل غير طبيعي) أو التليف الرئوي (تندب الرئة). تحدث مع طبيبك إذا عانيت من سعال أو عسر تنفس مستمر، سوائل في الرئتين أو داخل الصدر</li><li>مشاكل في الجيوب الأنفية.</li></ul><p dir="RTL"><strong>مشاكل</strong><strong> </strong><strong>أخرى</strong> مثل:</p><ul dir="rtl"><li>فقدان الوزن، النقرس، ارتفاع مستوى السكر في الدم، نزيف، كدمات.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &ldquo;EXP&rdquo;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي ميكوفينوليت موفيتيل.</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة من مايورا 500 ملغم أقراص مغطاة بطبقة رقيقة على 500 ملغم ميكوفينوليت موفيتيل.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي بوﭬيدون، كروسكارميللوز الصوديوم، سيلليلوز بلوري مكروي، ستيرات المغنيسيوم<em> </em>وأوبادري رمادي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مايورا 500 ملغم أقراص مغطاة بطبقة رقيقة هي أقراص ذات لون أرجواني شاحب، على شكل كبسولات مغطاة بطبقة رقيقة منقوش عليها &quot;MH6&quot; في أشرطة من الألومنيوم.</p><p dir="RTL">حجم العبوة: 50 قرص مغطى بطبقة رقيقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك</strong><strong> </strong><strong>رخصة<strong> </strong>التسويق&nbsp;</strong><br />شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني:SAPV@hikma.com</p><p dir="RTL"><strong>الشركة<strong> </strong>المصنعة&nbsp;</strong><br />الشركة العربية لصناعة الأدوية المساهمة الخاصة&nbsp;<br />سحاب<br />المدينة الصناعية<br />صندوق بريد 41<br />عمان 11512، الأردن<br />هاتف: 4023916(6-962) +<br />فاكس: 4023917 (6-962) +</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية&nbsp;</strong><br />تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي&nbsp;<br />مركز الاتصال الموحد: 19999&nbsp;<br />البريد الإلكتروني: npc.drug@sfda.gov.sa&nbsp;<br />الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 08/2024؛ رقم النسخة SA3.0.

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Myora 500 mg Film-coated Tablets




            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet of Myora 500 mg Film-coated Tablets contains 500 mg mycophenolate mofetil.

Excipient with known effect: Sodium.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets.

Lavender coloured, capsule-shaped film-coated tablets embossed with “MH6”.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Myora is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Posology</em></strong><br />Treatment should be initiated and maintained by appropriately qualified transplant specialists.</p><p><strong>Use in renal transplant</strong><br /><em>Adults</em><br />Treatment should be initiated within 72 hours following transplantation. The recommended dose in renal transplant patients is 1 g administered twice daily (2 g daily dose).</p><p><em>Paediatric population aged 2 to 18 years</em><br />The recommended dose of mycophenolate mofetil is 600 mg/m<sup>2&nbsp;</sup>administered orally twice daily (up to a maximum of 2 g daily). Tablets should only be prescribed to patients with a body surface area greater than 1.5 m<sup>2</sup>, at a dose of 1 g twice daily (2 g daily dose). As some adverse reactions occur with greater frequency in this age group (see section 4.8) compared with adults, temporary dose reduction or interruption may be required; these will need to take into account relevant clinical factors including severity of reaction.</p><p><em>Paediatric population &lt; 2 years</em><br />There are limited safety and efficacy data in children below the age of 2 years. These are insufficient to make dosage recommendations and therefore use in this age group is not recommended.</p><p><strong>Use in cardiac transplant</strong><br /><em>Adults</em><br />Treatment should be initiated within 5 days following transplantation. The recommended dose in cardiac transplant patients is 1.5 g administered twice daily (3 g daily dose).</p><p><em>Paediatric population</em><br />No data are available for paediatric cardiac transplant patients.</p><p><strong>Use in hepatic transplant</strong><br /><em>Adults</em><br />Intravenous (IV) Myora should be administered for the first 4 days following hepatic transplant, with oral Myora initiated as soon after this as it can be tolerated. The recommended oral dose in hepatic transplant patients is 1.5 g administered twice daily (3 g daily dose).</p><p><em>Paediatric population</em><br />No data are available for paediatric hepatic transplant patients.</p><p><strong>Use in special populations</strong><br /><em>Elderly</em><br />The recommended dose of 1 g administered twice a day for renal transplant patients and 1.5 g twice a day for cardiac or hepatic transplant patients is appropriate for the elderly.</p><p><em>Renal impairment</em><br />In renal transplant patients with severe chronic renal impairment (glomerular filtration rate &lt; 25 ml/min/1.73 m<sup>2</sup>), outside the immediate post-transplant period, doses greater than 1 g administered twice a day should be avoided. These patients should also be carefully observed. No dose adjustments are needed in patients experiencing delayed renal graft function post-operatively (see section 5.2). No data are available for cardiac or hepatic transplant patients with severe chronic renal impairment.</p><p><em>Severe hepatic impairment</em><br />No dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease. No data are available for cardiac transplant patients with severe hepatic parenchymal disease.</p><p><em>Treatment during rejection episodes</em><br />Mycophenolic acid (MPA) is the active metabolite of mycophenolate mofetil. Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of Myora is not required. There is no basis for Myora dose adjustment following cardiac transplant rejection. No pharmacokinetic data are available during hepatic transplant rejection.</p><p><em>Paediatric population</em><br />No data are available for treatment of first or refractory rejection in paediatric transplant patients.</p><p><strong><em>Method of administration</em></strong><br />For oral use.</p><p>Precautions to be taken before handling or administering the medicinal product.</p><p>Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, tablets should not be crushed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Myora should not be given to patients with hypersensitivity to mycophenolate mofetil, mycophenolic acid or to any of the excipients listed in section 6.1. Hypersensitivity reactions to Myora have been observed (see section 4.8).
• Myora should not be given to women of childbearing potential who are not using highly effective contraception (see section 4.6).
• Myora treatment should not be initiated in women of childbearing potential without providing a pregnancy test result to rule out unintended use in pregnancy (see section 4.6).
• Myora should not be used during pregnancy unless there is no suitable alternative treatment to prevent transplant rejection (see section 4.6).
• Myora should not be given to women who are breastfeeding (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Neoplasms</u><br />Patients receiving immunosuppressive regimens involving combinations of medicinal products, including Myora, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8). The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent. As general advice to minimise the risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.</p><p><u>Infections</u><br />Patients treated with immunosuppressants, including Myora, are at increased risk for opportunistic infections (bacterial, fungal, viral and protozoal), fatal infections and sepsis (see section 4.8). Such infections include latent viral reactivation, such as hepatitis B or hepatitis C reactivation and infections caused by polyomaviruses (BK virus-associated nephropathy, JC virus-associated progressive multifocal leukoencephalopathy PML). Cases of hepatitis due to reactivation of hepatitis B or hepatitis C have been reported in carrier patients treated with immunosuppressants. These infections are often related to a high total immunosuppressive burden and may lead to serious or fatal conditions that physicians should consider in the differential diagnosis in immunosuppressed patients with deteriorating renal function or neurological symptoms. Mycophenolic acid has a cytostatic effect on B- and T-lymphocytes, therefore an increased severity of COVID-19 may occur, and appropriate clinical action should be considered.</p><p>There have been reports of hypogammaglobulinaemia in association with recurrent infections in patients receiving mycophenolate mofetil<strong> </strong>in combination with other immunosuppressants. In some of these cases switching mycophenolate mofetil<strong> </strong>to an alternative immunosuppressant resulted in serum IgG levels returning to normal. Patients on mycophenolate mofetil<strong> </strong>who develop recurrent infections should have their serum immunoglobulins measured. In cases of sustained, clinically relevant hypogammaglobulinaemia, appropriate clinical action should be considered taking into account the potent cytostatic effects that mycophenolic acid has on T- and B-lymphocytes.</p><p>There have been published reports of bronchiectasis in adults and children who received mycophenolate mofetil<strong> </strong>in combination with other immunosuppressants. In some of these cases switching mycophenolate mofetil<strong> </strong>to another immunosuppressant resulted in improvement in respiratory symptoms. The risk of bronchiectasis may be linked to hypogammaglobulinaemia or to a direct effect on the lung. There have also been isolated reports of interstitial lung disease and pulmonary fibrosis, some of which were fatal (see section 4.8). It is recommended that patients who develop persistent pulmonary symptoms, such as cough and dyspnoea, are investigated.</p><p><u>Blood and immune system</u><br />Patients receiving mycophenolate mofetil<strong> </strong>should be monitored for neutropenia, which may be related to mycophenolate mofetil<strong> </strong>itself, concomitant medications, viral infections, or some combination of these causes. Patients taking mycophenolate mofetil<strong> </strong>should have complete blood counts weekly during the first month, twice monthly for the second and third months of treatment, then monthly through the first year. If neutropenia develops (absolute neutrophil count &lt; 1.3 x 10<sup>3</sup>/&micro;l), it may be appropriate to interrupt or discontinue mycophenolate mofetil.</p><p>Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolate mofetil<strong> </strong>in combination with other immunosuppressants. The mechanism for mycophenolate mofetil induced PRCA is unknown. PRCA may resolve with dose reduction or cessation of mycophenolate mofetil<strong> </strong>therapy. Changes to mycophenolate mofetil<strong> </strong>therapy should only be undertaken under appropriate supervision in transplant recipients in order to minimise the risk of graft rejection (see section 4.8).</p><p>Patients receiving mycophenolate mofetil<strong> </strong>should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow failure.</p><p>Patients should be advised that, during treatment with mycophenolate mofetil, vaccinations may be less effective, and the use of live attenuated vaccines should be avoided (see section 4.5). Influenza vaccination may be of value. Prescribers should refer to national guidelines for influenza vaccination.</p><p><u>Gastro-intestinal</u><br />Mycophenolate mofetil<strong> </strong>has been associated with an increased incidence of digestive system adverse events, including infrequent cases of gastrointestinal tract ulceration, haemorrhage and perforation. Mycophenolate mofetil<strong> </strong>should be administered with caution in patients with active serious digestive system disease.</p><p>Mycophenolate mofetil<strong> </strong>is an IMPDH (inosine monophosphate dehydrogenase) inhibitor. Therefore, it should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndrome.</p><p><u>Interactions</u><br />Caution should be exercised when switching combination therapy from regimens containing immunosuppressants, which interfere with MPA enterohepatic recirculation, e.g. ciclosporin, to others devoid of this effect, e.g. tacrolimus, sirolimus, belatacept, or vice versa, as this might result in changes of MPA exposure. Drugs which interfere with MPA&#39;s enterohepatic cycle (e.g. cholestyramine, antibiotics) should be used with caution due to their potential to reduce the plasma level and efficacy of mycophenolate mofetil<strong> </strong>(see also section 4.5). Therapeutic drug monitoring of MPA may be appropriate when switching combination therapy (e.g. from ciclosporin to tacrolimus or vice versa) or to ensure adequate immunosuppression in patients with high immunological risk (e.g. risk of rejection, treatment with antibiotics, addition or removal of an interacting medication).</p><p>It is recommended that mycophenolate mofetil<strong> </strong>should not be administered concomitantly with azathioprine because such concomitant administration has not been studied.</p><p>The risk/benefit ratio of mycophenolate mofetil in combination with sirolimus has not been established (see also section 4.5).</p><p><u>Special populations</u><br />Elderly patients may be at an increased risk of adverse events such as certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared with younger individuals (see section 4.8).</p><p><u>Teratogenic effects</u><br />Mycophenolate is a powerful human teratogen. Spontaneous abortion (rate of 45% to 49%) and congenital malformations (estimated rate of 23% to 27%) have been reported following MMF exposure during pregnancy. Therefore, mycophenolate mofetil<strong> </strong>is contraindicated in pregnancy unless there are no suitable alternative treatments to prevent transplant rejection. Female patients of childbearing potential should be made aware of the risks and follow the recommendations provided in section 4.6 (e.g. contraceptive methods, pregnancy testing) prior to, during, and after therapy with mycophenolate mofetil. Physicians should ensure that women taking mycophenolate understand the risk of harm to the baby, the need for effective contraception, and the need to immediately consult their physician if there is a possibility of pregnancy.</p><p><u>Contraception (see section 4.6)</u><br />Because of robust clinical evidence showing a high risk of abortion and congenital malformations when mycophenolate mofetil is used in pregnancy, every effort to avoid pregnancy during treatment should be taken. Therefore, women with childbearing potential must use at least one form of reliable contraception (see section 4.3) before starting mycophenolate mofetil<strong> </strong>therapy, during therapy, and for six weeks after stopping the therapy, unless abstinence is the chosen method of contraception. Two complementary forms of contraception simultaneously are preferred to minimise the potential for contraceptive failure and unintended pregnancy.</p><p>For contraception advice for men see section 4.6.</p><p><u>Educational materials</u><br />In order to assist patients in avoiding foetal exposure to mycophenolate and to provide additional important safety information, the Marketing Authorisation Holder will provide educational materials to healthcare professionals. The educational materials will reinforce the warnings about the teratogenicity of mycophenolate, provide advice on contraception before therapy is started and guidance on the need for pregnancy testing. Full patient information about the teratogenic risk and the pregnancy prevention measures should be given by the physician to women of childbearing potential and, as appropriate, to male patients.</p><p><u>Additional precautions</u><br />Patients should not donate blood during therapy or for at least 6 weeks following discontinuation of mycophenolate. Men should not donate semen during therapy or for 90 days following discontinuation of mycophenolate.</p><p><strong>Myora contains sodium</strong><br />Myora contains sodium. Each film-coated tablet of Myora 500 mg Film-coated Tablets contains 6.74 mg sodium. This medicine contains less than 1 mmol sodium (23 mg) per film coated tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Aciclovir</strong><br />Higher aciclovir plasma concentrations were observed when mycophenolate mofetil was administered with aciclovir in comparison to the administration of aciclovir alone. The changes in MPAG (the phenolic glucuronide of MPA) pharmacokinetics (MPAG increased by 8%) were minimal and are not considered clinically significant. Because MPAG plasma concentrations are increased in the presence of renal impairment, as are aciclovir concentrations, the potential exists for mycophenolate mofetil and aciclovir, or its prodrugs, e.g. valaciclovir, to compete for tubular secretion and further increases in concentrations of both substances may occur.</p><p><strong>Antacids and proton pump inhibitors (PPIs)</strong><br />Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between mycophenolate mofetil<strong> </strong>pt patients taking PPIs vs. mycophenolate mofetil<strong> </strong>patients not taking PPIs, no significant differences were seen. These data support extrapolation of this finding to all antacids because the reduction in exposure when mycophenolate mofetil<strong> </strong>was co- administered with magnesium and aluminium hydroxides is considerably less than when mycophenolate mofetil<strong> </strong>was co-administered with PPIs.</p><p><strong>Medicinal products that interfere with enterohepatic recirculation (e.g. cholestyramine, ciclosporin A, antibiotics)</strong><br />Caution should be used with medicinal products that interfere with enterohepatic recirculation because of their potential to reduce the efficacy of mycophenolate mofetil.</p><p><em>Cholestyramine</em><br />Following single dose administration of 1.5 g of mycophenolate mofetil to normal healthy subjects pre-treated with 4 g TID of cholestyramine for 4 days, there was a 40% reduction in the AUC of MPA (see section 4.4 and section 5.2). Caution should be used during concomitant administration because of the potential to reduce efficacy of mycophenolate mofetil.</p><p><em>Ciclosporin A</em><br />Ciclosporin A (CsA) pharmacokinetics are unaffected by mycophenolate mofetil.</p><p>In contrast, if concomitant CsA treatment is stopped, an increase in MPA AUC of around 30% should be expected. CsA interferes with MPA enterohepatic recycling, resulting in reduced MPA exposures by 30 - 50% in renal transplant patients treated with mycophenolate mofetil<strong> </strong>and CsA compared with patients receiving sirolimus or belatacept and similar doses of mycophenolate mofetil<strong> </strong>(see also section 4.4). Conversely, changes of MPA exposure should be expected when switching patients from CsA to one of the immunosuppressants which does not interfere with MPA&#39;s enterohepatic cycle.</p><p>Antibiotics eliminating &beta;-glucuronidase-producing bacteria in the intestine (e.g. aminoglycoside, cephalosporin, fluoroquinolone, and penicillin classes of antibiotics) may interfere with MPAG/MPA enterohepatic recirculation, thus leading to reduced systemic MPA exposure. Information concerning the following antibiotics is available:</p><p><em>Ciprofloxacin or amoxicillin plus clavulanic acid</em><br />Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal transplant recipients in the days immediately following commencement of oral ciprofloxacin or amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to cease within a few days of antibiotic discontinuation. The change in pre-dose level may not accurately represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil<strong> </strong>should not normally be necessary in the absence of clinical evidence of graft dysfunction. However, close clinical monitoring should be performed during the combination and shortly after antibiotic treatment.</p><p><em>Norfloxacin and metronidazole</em><br />In healthy volunteers, no significant interaction was observed when mycophenolate mofetil<strong> </strong>was concomitantly administered with norfloxacin or metronidazole separately. However, norfloxacin and metronidazole combined reduced the MPA exposure by approximately 30% following a single dose of mycophenolate mofetil.</p><p><em>Trimethoprim/sulfamethoxazole</em><br />No effect on the bioavailability of MPA was observed.</p><p><strong>Medicinal products that affect glucuronidation (e.g. isavuconazole, telmisartan)</strong><br />Concomitant administration of drugs affecting glucuronidation of MPA may change MPA exposure. Caution is therefore recommended when administering these drugs concomitantly with mycophenolate mofetil.</p><p><em>Isavuconazole</em><br />An increase of MPA exposure (AUC<sub>0-&infin;</sub>) by 35% was observed with concomitant administration of isavuconazole.</p><p><em>Telmisartan</em><br />Concomitant administration of telmisartan and mycophenolate mofetil<strong> </strong>resulted in an approximately 30% decrease of MPA concentrations. Telmisartan changes MPA&#39;s elimination by enhancing PPAR gamma (peroxisome proliferator-activated receptor gamma) expression, which in turn results in an enhanced uridine diphosphate glucuronyltransferase isoform 1A9 (UGT1A9) expression and activity. When comparing rates of transplant rejection, rates of graft loss or adverse event profiles between mycophenolate mofetil<strong> </strong>patients with and without concomitant telmisartan medication, no clinical consequences of the pharmacokinetic drug-drug interaction were seen.</p><p><em>Ganciclovir</em><br />Based on the results of a single dose administration study of recommended doses of oral mycophenolate and IV ganciclovir and the known effects of renal impairment on the pharmacokinetics of mycophenolate mofetil<strong> </strong>(see section 4.2) and ganciclovir, it is anticipated that co-administration of these agents (which compete for mechanisms of renal tubular secretion) will result in increases in MPAG and ganciclovir concentration. No substantial alteration of MPA pharmacokinetics is anticipated and mycophenolate mofetil<strong> </strong>dose adjustment is not required. In patients with renal impairment in whom mycophenolate mofetil<strong> </strong>and ganciclovir or its prodrugs, e.g. valganciclovir, are co-administered, the dose recommendations for ganciclovir should be observed and patients should be monitored carefully.</p><p><em>Oral contraceptives</em><br />The pharmacodynamics and pharmacokinetics of oral contraceptives were not affected to a clinically relevant degree by co-administration of mycophenolate mofetil<strong> </strong>(see also section 5.2).</p><p><em>Rifampicin</em><br />In patients not also taking ciclosporin, concomitant administration of mycophenolate mofetil<strong> </strong>and rifampicin resulted in a decrease in MPA exposure (AUC<sub>0-12h</sub>) of 18% to 70%. It is recommended to monitor MPA exposure levels and to adjust mycophenolate mofetil<strong> </strong>doses accordingly to maintain clinical efficacy when rifampicin is administered concomitantly.</p><p><em>Sevelamer</em><br />Decrease in MPA C<sub>max</sub>&nbsp;and AUC<sub>0-12h</sub>&nbsp;by 30% and 25%, respectively, were observed when mycophenolate mofetil<strong> </strong>was concomitantly administered with sevelamer without any clinical consequences (i.e. graft rejection). It is recommended, however, to administer mycophenolate mofetil<strong> </strong>at least one hour before or three hours after sevelamer intake to minimise the impact on the absorption of MPA. There are no data on mycophenolate mofetil<strong> </strong>with phosphate binders other than sevelamer.</p><p><em>Tacrolimus</em><br />In hepatic transplant patients initiated on mycophenolate mofetil<strong> </strong>and tacrolimus, the AUC and C<sub>max</sub>&nbsp;of MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by co-administration with tacrolimus. In contrast, there was an increase of approximately 20% in tacrolimus AUC when multiple doses of mycophenolate mofetil<strong> </strong>(1.5 g BID) were administered to hepatic transplant patients taking tacrolimus. However, in renal transplant patients, tacrolimus concentration did not appear to be altered by mycophenolate mofetil<strong> </strong>(see also section 4.4).</p><p><em>Live vaccines</em><br />Live vaccines should not be given to patients with an impaired immune response. The antibody response to other vaccines may be diminished (see also 4.4).</p><p><em>Paediatric population</em><br />Interaction studies have only been performed in adults.</p><p><strong>Potential interaction</strong><br />Co-administration of probenecid with mycophenolate mofetil in monkeys raises plasma AUC of MPAG by 3-fold. Thus, other substances known to undergo renal tubular secretion may compete with MPAG, and thereby raise plasma concentrations of MPAG or the other substance undergoing tubular secretion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Women of childbearing potential</strong><br />Pregnancy whilst taking mycophenolate must be avoided. Therefore, women of childbearing potential must use at least one form of reliable contraception (see section 4.3) before starting mycophenolate mofetil<strong> </strong>therapy, during therapy, and for six weeks after stopping the therapy, unless abstinence is the chosen method of contraception. Two complementary forms of contraception simultaneously are preferred.</p><p><strong>Pregnancy</strong><br />Mycophenolate mofetil<strong> </strong>is contraindicated during pregnancy unless there is no suitable alternative treatment to prevent transplant rejection. Treatment should not be initiated without providing a negative pregnancy test result to rule out unintended use in pregnancy (see section 4.3).</p><p>Female patients of reproductive potential must be made aware of the increased risk of pregnancy loss and congenital malformations at the beginning of the treatment and must be counselled regarding pregnancy prevention and planning.</p><p>Before starting mycophenolate mofetil<strong> </strong>treatment, women of childbearing potential should have two negative serum or urine pregnancy tests with a sensitivity of at least 25 mIU/ml in order to exclude unintended exposure of an embryo to mycophenolate. It is recommended that the second test should be performed 8 - 10 days after the first test. For transplants from deceased donors, if it is not possible to perform two tests 8 - 10 days apart before treatment starts (because of the timing of transplant organ availability), a pregnancy test must be performed immediately before starting treatment and a further test 8 - 10 days later. Pregnancy tests should be repeated as clinically required (e.g. after any gap in contraception is reported). Results of all pregnancy tests should be discussed with the patient. Patients should be instructed to consult their physician immediately should pregnancy occur.</p><p>Mycophenolate is a powerful human teratogen, with an increased risk of spontaneous abortions and congenital malformations in case of exposure during pregnancy;</p><ul><li>Spontaneous abortions have been reported in 45 to 49% of pregnant women exposed to mycophenolate mofetil, compared to a reported rate of between 12 and 33% in solid organ transplant patients treated with immunosuppressants other than mycophenolate mofetil.</li><li>Based on literature reports, malformations occurred in 23 to 27% of live births in women exposed to mycophenolate mofetil during pregnancy (compared to 2 to 3 % of live births in the overall population and approximately 4 to 5% of live births in solid organ transplant recipients treated with immunosuppressants other than mycophenolate mofetil).</li></ul><p>Congenital malformations, including reports of multiple malformations, have been observed post-marketing in children of patients exposed to mycophenolate mofetil<strong> </strong>during pregnancy in combination with other immunosuppressants. The following malformations were most frequently reported:</p><ul><li>Abnormalities of the ear (e.g. abnormally formed or absent external ear), external auditory canal atresia (middle ear);</li><li>Facial malformations such as cleft lip, cleft palate, micrognathia and hypertelorism of the orbits;</li><li>Abnormalities of the eye (e.g. coloboma);</li><li>Congenital heart disease such as atrial and ventricular septal defects;</li><li>Malformations of the fingers (e.g. polydactyly, syndactyly);</li><li>Tracheo-oesophageal malformations (e.g. oesophageal atresia);</li><li>Nervous system malformations such as spina bifida;</li><li>Renal abnormalities.</li></ul><p>In addition, there have been isolated reports of the following malformations:</p><ul><li>Microphthalmia;</li><li>Congenital choroid plexus cyst;</li><li>Septum pellucidum agenesis;</li><li>Olfactory nerve agenesis.</li></ul><p>Studies in animals have shown reproductive toxicity (see section 5.3).</p><p><strong>Breast-feeding</strong><br />Limited data shows that mycophenolic acid is excreted in human milk. Because of the potential for serious adverse reactions to mycophenolic acid in breast-fed infants, CellCept is contraindicated in nursing mothers (see section 4.3).</p><p><strong>Men</strong><br />The limited clinical evidence available does not indicate an increased risk of malformations or miscarriage following paternal exposure to mycophenolate mofetil.</p><p>MPA is a powerful teratogen. It is not known if MPA is present in semen. Calculations based on animal data show that the maximum amount of MPA that could potentially be transferred to woman is so low that it would be unlikely to have an effect. Mycophenolate has been shown to be genotoxic in animal studies at concentrations exceeding the human therapeutic exposures only by small margins such that the risk of genotoxic effects on sperm cells cannot completely be excluded.</p><p>Therefore, the following precautionary measures are recommended: sexually active male patients or their female partners are recommended to use reliable contraception during treatment of the male patient and for at least 90 days after cessation of mycophenolate mofetil. Male patients of reproductive potential should be made aware of and discuss with a qualified healthcare professional the potential risks of fathering a child.</p><p><strong>Fertility</strong><br />Mycophenolate mofetil had no effect on fertility of male rats at oral doses up to 20 mg/kg/day. The systemic exposure at this dose represents 2 &ndash; 3 times the clinical exposure at the recommended clinical dose of 2 g/day in renal transplant patients and 1.3 &ndash; 2 times the clinical exposure at the recommended clinical dose of 3 g/day in cardiac transplant patients. In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg/kg/day caused malformations (including anophthalmia, agnathia, and hydrocephaly) in the first generation offspring in the absence of maternal toxicity. The systemic exposure at this dose was approximately 0.5 times the clinical exposure at the recommended clinical dose of 2 g/day for renal transplant patients and approximately 0.3 times the clinical exposure at the recommended clinical dose of 3 g/day for cardiac transplant patients. No effects on fertility or reproductive parameters were evident in the dams or in the subsequent generation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mycophenolate mofetil<strong> </strong>has a moderate influence on the ability to drive and use machines.</p><p>Mycophenolate mofetil<strong> </strong>may cause somnolence, confusion, dizziness, tremor or hypotension, and therefore patients are advised to use caution when driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong><br />Diarrhoea (up to 52.6%), leucopenia (up to 45.8%), bacterial infections (up to 39.9%) and vomiting (up to 39.1%) were among the most common and/or serious adverse reactions associated with the administration of mycophenolate mofetil<strong> </strong>in combination with ciclosporin and corticosteroids. There is evidence of a higher frequency of certain types of infections (see section 4.4).</p><p><strong>Tabulated list of adverse reactions</strong><br />The adverse reactions from clinical trials and post-marketing experience are listed in Table 1, by MedDRA system organ class (SOC) along with their frequencies. The corresponding frequency category for each adverse reaction is based on the following convention: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000). Due to the large differences observed in the frequency of certain adverse reactions across the different transplant indications, the frequency is presented separately for renal, hepatic and cardiac transplant patients.</p><p><strong>Table 1 Adverse reactions</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p><strong>Adverse reaction</strong></p><p><strong>(MedDRA)</strong></p><p><strong>System Organ Class</strong></p></td><td style="vertical-align:bottom"><p><strong>Renal transplant</strong></p></td><td style="vertical-align:bottom"><p><strong>Hepatic transplant</strong></p></td><td style="vertical-align:bottom"><p><strong>Cardiac transplant</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Frequency</p></td><td style="vertical-align:bottom"><p>Frequency</p></td><td style="vertical-align:bottom"><p>Frequency</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Bacterial infections</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Fungal infections</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Protozoal infections</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td></tr><tr><td style="vertical-align:bottom"><p>Viral infections</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Neoplasms benign, malignant and unspecified (including cysts and polyps)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Benign neoplasm of skin</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Lymphoma</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td></tr><tr><td style="vertical-align:bottom"><p>Lymphoproliferative disorder</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td></tr><tr><td style="vertical-align:bottom"><p>Neoplasm</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Skin cancer</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Anemia</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Aplasia pure red cell</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td></tr><tr><td style="vertical-align:bottom"><p>Bone marrow failure</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td></tr><tr><td style="vertical-align:bottom"><p>Ecchymosis</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Leukocytosis</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Leucopenia</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Pancytopenia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td></tr><tr><td style="vertical-align:bottom"><p>Pseudolymphoma</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Thrombocytopenia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Acidosis</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Hypercholesterolemia</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Hyperglycemia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Hyperkalemia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Hyperlipidemia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Hypocalcemia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Hypokalemia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Hypomagnesemia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Hypophosphatemia</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Hyperuricaemia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Gout</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Weight decreased</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Confusional state</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Depression</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Insomnia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Agitation</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Anxiety</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Thinking abnormal</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Dizziness</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Headache</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Hypertonia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Paresthesia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Somnolence</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Tremor</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Convulsion</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Dysgeusia</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Tachycardia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Hypertension</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Hypotension</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Lymphocele</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td></tr><tr><td style="vertical-align:bottom"><p>Venous thrombosis</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Vasodilatation</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Bronchiectasis</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td></tr><tr><td style="vertical-align:bottom"><p>Cough</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Dyspnea</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Interstitial lung disease</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Very Rare</p></td><td style="vertical-align:bottom"><p>Very Rare</p></td></tr><tr><td style="vertical-align:bottom"><p>Pleural effusion</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Pulmonary fibrosis</p></td><td style="vertical-align:bottom"><p>Very Rare</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Abdominal distension</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Abdominal pain</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Colitis</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Constipation</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Decreased appetite</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Diarrhea</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Dyspepsia</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Esophagitis</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Eructation</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Flatulence</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Gastritis</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Gastrointestinal hemorrhage</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Gastrointestinal ulcer</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Gingival hyperplasia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Ileus</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Mouth ulceration</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Nausea</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Pancreatitis</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td></tr><tr><td style="vertical-align:bottom"><p>Stomatitis</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Vomiting</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Hypersenstivity</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Hypogammaglobulinaemia</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Very Rare</p></td><td style="vertical-align:bottom"><p>Very Rare</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Blood alkaline phosphatase increased</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Blood lactate dehydrogenase increased</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Hepatic enzyme increased</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Hepatitis</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td></tr><tr><td style="vertical-align:bottom"><p>Hyperbilirubinaemia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Jaundice</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Acne</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Alopecia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Rash</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Skin hypertrophy</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Arthralgia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Muscular weakness</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Blood creatinine increased</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Blood urea increased</p></td><td style="vertical-align:bottom"><p>Uncommon</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Hematuria</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Renal impairment</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td colspan="4" style="vertical-align:bottom"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Asthenia</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Chills</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Oedema</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Hernia</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Malaise</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Pain</p></td><td style="vertical-align:bottom"><p>Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td style="vertical-align:bottom"><p>Pyrexia</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td><td style="vertical-align:bottom"><p>Very Common</p></td></tr><tr><td><p>De novo purine synthesis inhibitors associated acute inflammatory syndrome</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td></tr></tbody></table><p><strong>Description of selected adverse reactions</strong><br /><em>Malignancies</em><br />Patients receiving immunosuppressive regimens involving combinations of medicinal products, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.4). Three-year safety data in renal and cardiac transplant patients did not reveal any unexpected changes in incidence of malignancy compared to the 1-year data. Hepatic transplant patients were followed for at least 1 year, but less than 3 years.</p><p><em>Infections</em><br />All patients treated with immunosuppressants are at increased risk of bacterial, viral and fungal infections (some of which may lead to a fatal outcome), including those caused by opportunistic agents and latent viral reactivation. The risk increases with total immunosuppressive load (see section 4.4). The most serious infections were sepsis, peritonitis, meningitis, endocarditis, tuberculosis and atypical mycobacterial infection. The most common opportunistic infections in patients receiving mycophenolate mofetil<strong> </strong>(2 g or 3 g daily) with other immunosuppressants in controlled clinical trials in renal, cardiac and hepatic transplant patients followed for at least 1 year were candida mucocutaneous, CMV viraemia/syndrome and Herpes simplex. The proportion of patients with CMV viraemia/syndrome was 13.5%. Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leukoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including mycophenolate mofetil.</p><p><em>Blood and lymphatic disorders</em><br />Cytopenias, including leucopenia, anemia, thrombocytopenia and pancytopenia, are known risks associated with mycophenolate mofetil and may lead or contribute to the occurrence of infections and hemorrhages (see section 4.4). Agranulocytosis and neutropenia have been reported; therefore, regular monitoring of patients taking mycophenolate mofetil<strong> </strong>is advised (see section 4.4). There have been reports of aplastic anaemia and bone marrow failure in patients treated with mycophenolate mofetil, some of which have been fatal.</p><p>Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolate mofetil<strong> </strong>(see section 4.4).</p><p>Isolated cases of abnormal neutrophil morphology, including the acquired Pelger-Huet anomaly, have been observed in patients treated with mycophenolate mofetil. These changes are not associated with impaired neutrophil function. These changes may suggest a &#39;left shift&#39; in the maturity of neutrophils in haematological investigations, which may be mistakenly interpreted as a sign of infection in immunosuppressed patients such as those that receive mycophenolate mofetil.</p><p><em>Gastrointestinal disorders</em><br />The most serious gastrointestinal disorders were ulceration and hemorrhage which are known risks associated with mycophenolate mofetil. Mouth, esophageal, gastric, duodenal, and intestinal ulcers often complicated by hemorrhage, as well as hematemesis, melena, and hemorrhagic forms of gastritis and colitis were commonly reported during the pivotal clinical trials. The most common gastrointestinal disorders, however, were diarrhoea, nausea and vomiting. Endoscopic investigation of patients with mycophenolate mofetil<strong> </strong>-related diarrhoea have revealed isolated cases of intestinal villous atrophy (see section 4.4).</p><p><em>Hypersensitivity</em><br />Hypersensitivity reactions, including angioneurotic oedema and anaphylactic reaction have been reported.</p><p><em>Pregnancy, puerperium and perinatal conditions</em><br />Cases of spontaneous abortion have been reported in patients exposed to mycophenolate mofetil, mainly in the first trimester, see section 4.6.</p><p><em>Congenital disorders</em><br />Congenital malformations have been observed post-marketing in children of patients exposed to mycophenolate mofetil<strong> </strong>in combination with other immunosuppressants, see section 4.6.</p><p><em>Respiratory, thoracic and mediastinal disorders</em><br />There have been isolated reports of interstitial lung disease and pulmonary fibrosis in patients treated with mycophenolate mofetil<strong> </strong>in combination with other immunosuppressants, some of which have been fatal. There have also been reports of bronchiectasis in children and adults.</p><p><em>Immune system disorders</em><br />Hypogammaglobulinaemia has been reported in patients receiving mycophenolate mofetil<strong> </strong>in combination with other immunosuppressants.</p><p><em>General disorders and administration site conditions</em><br />Oedema, including peripheral, face and scrotal oedema, was reported very commonly during the pivotal trials. Musculoskeletal pain such as myalgia, and neck and back pain were also very commonly reported.</p><p>De novo purine synthesis inhibitors associated acute inflammatory syndrome has been described from post-marketing experience as a paradoxical proinflammatory reaction associated with mycophenolate mofetil and mycophenolic acid, characterised by fever, arthralgia, arthritis, muscle pain and elevated inflammatory markers. Literature case reports showed rapid improvement following discontinuation of the medicinal product.</p><p><strong>Special populations</strong><br /><em>Paediatric population</em><br />The type and frequency of adverse reactions in a clinical study, which recruited 92 paediatric patients aged 2 to 18 years who were given 600 mg/m<sup>2</sup>&nbsp;mycophenolate mofetil orally twice daily, were generally similar to those observed in adult patients given 1 g mycophenolate mofetil<strong> </strong>twice daily. However, the following treatment-related adverse events were more frequent in the paediatric population, particularly in children under 6 years of age, when compared to adults: diarrhoea, sepsis, leucopenia, anaemia and infection.</p><p><em>Elderly</em><br />Elderly patients (&ge; 65 years) may generally be at increased risk of adverse reactions due to immunosuppression. Elderly patients receiving mycophenolate mofetil<strong> </strong>as part of a combination immunosuppressive regimen, may be at increased risk of certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared to younger individuals.</p><p><strong>Reporting of suspected adverse reactions</strong><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports of overdoses with mycophenolate mofetil have been received from clinical trials and during post-marketing experience. In many of these cases, no adverse events were reported. In those overdose cases in which adverse events were reported, the events fall within the known safety profile of the medicinal product.</p><p>It is expected that an overdose of mycophenolate mofetil could possibly result in oversuppression of the immune system and increase susceptibility to infections and bone marrow suppression (see section 4.4). If neutropenia develops, dosing with mycophenolate mofetil<strong> </strong>should be interrupted or the dose reduced (see section 4.4).</p><p>Haemodialysis would not be expected to remove clinically significant amounts of MPA or MPAG. Bile acid sequestrants, such as cholestyramine, can remove MPA by decreasing the enterohepatic recirculation of the drug (see section 5.2).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: immunosuppressive agents ATC code L04AA06.</p><p><strong>Mechanism of action</strong><br />Mycophenolate mofetil is the 2-morpholinoethyl ester of MPA. MPA is a selective, uncompetitive and reversible inhibitor of IMPDH, and therefore inhibits the&nbsp;<em>de novo</em>&nbsp;pathway of guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-lymphocytes are critically dependent for their proliferation on&nbsp;<em>de novo</em>&nbsp;synthesis of purines whereas other cell types can utilise salvage pathways, MPA has more potent cytostatic effects on lymphocytes than on other cells.</p><p>In addition to its inhibition of IMPDH and the resulting deprivation of lymphocytes, MPA also influences cellular checkpoints responsible for metabolic programming of lymphocytes. It has been shown, using human CD4+ T-cells, that MPA shifts transcriptional activities in lymphocytes from a proliferative state to catabolic processes relevant to metabolism and survival leading to an anergic state of T-cells, whereby the cells become unresponsive to their specific antigen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong><br />Following oral administration, mycophenolate mofetil undergoes rapid and extensive absorption and complete presystemic metabolism to the active metabolite, MPA. As evidenced by suppression of acute rejection following renal transplantation, the immunosuppressant activity of mycophenolate mofetil<strong> </strong>is correlated with MPA concentration. The mean bioavailability of oral mycophenolate mofetil, based on MPA AUC, is 94% relative to IV mycophenolate mofetil. Food had no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil when administered at doses of 1.5 g BID to renal transplant patients. However, MPA C<sub>max</sub>&nbsp;was decreased by 40% in the presence of food.</p><p>Mycophenolate mofetil is not measurable systemically in plasma following oral administration.</p><p><strong>Distribution</strong><br />As a result of enterohepatic recirculation, secondary increases in plasma MPA concentration are usually observed at approximately 6 &ndash; 12 hours post-dose. A reduction in the AUC of MPA of approximately 40% is associated with the co-administration of cholestyramine (4 g TID), indicating that there is a significant amount of enterohepatic recirculation.</p><p>MPA at clinically relevant concentrations is 97% bound to plasma albumin.</p><p>In the early post-transplant period (&lt; 40 days post-transplant), renal, cardiac and hepatic transplant patients had mean MPA AUCs approximately 30% lower and C<sub>max</sub>&nbsp;approximately 40% lower compared to the late post-transplant period (3 - 6 months post-transplant).</p><p><strong>Biotransformation</strong><br />MPA is metabolised principally by glucuronyl transferase (isoform UGT1A9) to form the inactive phenolic glucuronide of MPA (MPAG).&nbsp;<em>In vivo</em>, MPAG is converted back to free MPA via enterohepatic recirculation. A minor acylglucuronide (AcMPAG) is also formed. AcMPAG is pharmacologically active and is suspected to be responsible for some of MMF&#39;s side effects (diarrhoea, leucopenia).</p><p><strong>Elimination</strong><br />A negligible amount of substance is excreted as MPA (&lt; 1% of the dose) in the urine. Oral administration of radiolabelled mycophenolate mofetil results in complete recovery of the administered dose with 93% of the administered dose recovered in the urine and 6% recovered in the faeces. Most (about 87%) of the administered dose is excreted in the urine as MPAG.</p><p>At clinically encountered concentrations, MPA and MPAG are not removed by haemodialysis. However, at high MPAG plasma concentrations (&gt; 100 &micro;g/ml), small amounts of MPAG are removed. By interfering with enterohepatic recirculation of the drug, bile acid sequestrants such as cholestyramine, reduce MPA AUC (see section 4.9).</p><p>MPA&#39;s disposition depends on several transporters. Organic anion-transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are involved in MPA&#39;s disposition; OATP isoforms, MRP2 and breast cancer resistance protein (BCRP) are transporters associated with the glucuronides&#39; biliary excretion. Multidrug resistance protein 1 (MDR1) is also able to transport MPA, but its contribution seems to be confined to the absorption process. In the kidney, MPA and its metabolites potently interact with renal organic anion transporters.</p><p>Enterohepatic recirculation interferes with accurate determination of MPA&#39;s disposition parameters; only apparent values can be indicated. In healthy volunteers and patients with autoimmune disease approximate clearance values of 10.6 L/h and 8.27 L/h respectively and half-life values of 17 h were observed. In transplant patients mean clearance values were higher (range 11.9-34.9 L/h) and mean half-life values shorter (5-11 h) with little difference between renal, hepatic or cardiac transplant patients. In the individual patients, these elimination parameters vary based on type of co-treatment with other immunosuppressants, time post-transplantation, plasma albumin concentration and renal function. These factors explain why reduced exposure is seen when mycophenolate mofetil<strong> </strong>is co-administered with cyclosporine (see section 4.5) and why plasma concentrations tend to increase over time compared to what is observed immediately after transplantation.</p><p><strong>Special populations</strong><br /><em>Renal impairment</em><br />In a single dose study (6 subjects/group), mean plasma MPA AUC observed in subjects with severe chronic renal impairment (glomerular filtration rate &lt; 25 ml/min/1.73 m<sup>2</sup>) were 28 &ndash; 75% higher relative to the means observed in normal healthy subjects or subjects with lesser degrees of renal impairment. The mean single dose MPAG AUC was 3 &ndash; 6-fold higher in subjects with severe renal impairment than in subjects with mild renal impairment or normal healthy subjects, consistent with the known renal elimination of MPAG. Multiple dosing of mycophenolate mofetil in patients with severe chronic renal impairment has not been studied. No data are available for cardiac or hepatic transplant patients with severe chronic renal impairment.</p><p><em>Delayed renal graft function</em><br />In patients with delayed renal graft function post-transplant, mean MPA AUC<sub>0-12h</sub>&nbsp;was comparable to that seen in post-transplant patients without delayed graft function. Mean plasma MPAG AUC<sub>0-12h</sub>&nbsp;was 2 &ndash; 3-fold higher than in post-transplant patients without delayed graft function. There may be a transient increase in the free fraction and concentration of plasma MPA in patients with delayed renal graft function. Dose adjustment of mycophenolate mofetil<strong> </strong>does not appear to be necessary.</p><p><em>Hepatic impairment</em><br />In volunteers with alcoholic cirrhosis, hepatic MPA glucuronidation processes were relatively unaffected by hepatic parenchymal disease. Effects of hepatic disease on these processes probably depend on the particular disease. Hepatic disease with predominantly biliary damage, such as primary biliary cirrhosis, may show a different effect.</p><p><em>Paediatric population</em><br />Pharmacokinetic parameters were evaluated in 49 paediatric renal transplant patients (aged 2 to 18 years) given 600 mg/m<sup>2</sup>&nbsp;mycophenolate mofetil orally twice daily. This dose achieved MPA AUC values similar to those seen in adult renal transplant patients receiving mycophenolate mofetil<strong> </strong>at a dose of 1 g BID in the early and late post-transplant period. MPA AUC values across age groups were similar in the early and late post-transplant period.</p><p><em>Elderly</em><br />The pharmacokinetics of mycophenolate mofetil and its metabolites have not been found to be altered in the elderly patients (&ge; 65 years) when compared to younger transplant patients.</p><p><em>Patients taking oral contraceptives</em><br />A study of the co-administration of mycophenolate mofetil<strong> </strong>(1 g BID) and combined oral contraceptives containing ethinylestradiol (0.02 mg to 0.04 mg) and levonorgestrel (0.05 mg to 0.20 mg), desogestrel (0.15 mg) or gestodene (0.05 mg to 0.10 mg) conducted in 18 non-transplant women (not taking other immunosuppressants) over 3 consecutive menstrual cycles showed no clinically relevant influence of mycophenolate mofetil<strong> </strong>on the ovulation-suppressing action of the oral contraceptives. Serum levels of LH, FSH and progesterone were not significantly affected. The pharmacokinetics of oral contraceptives were not affected to a clinically relevant degree by co-administration of mycophenolate mofetil<strong> </strong>(see also section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In experimental models, mycophenolate mofetil was not tumourigenic. The highest dose tested in the animal carcinogenicity studies resulted in approximately 2 &ndash; 3 times the systemic exposure (AUC or C<sub>max</sub>) observed in renal transplant patients at the recommended clinical dose of 2 g/day and 1.3 &ndash; 2 times the systemic exposure (AUC or C<sub>max</sub>) observed in cardiac transplant patients at the recommended clinical dose of 3 g/day.</p><p>Two genotoxicity assays (<em>in vitro</em>&nbsp;mouse lymphoma assay and&nbsp;<em>in vivo</em>&nbsp;mouse bone marrow micronucleus test) showed a potential of mycophenolate mofetil to cause chromosomal aberrations. These effects can be related to the pharmacodynamic mode of action, i.e. inhibition of nucleotide synthesis in sensitive cells. Other&nbsp;<em>in vitro</em>&nbsp;tests for detection of gene mutation did not demonstrate genotoxic activity.</p><p>In teratology studies in rats and rabbits, foetal resorptions and malformations occurred in rats at 6 mg/kg/day (including anophthalmia, agnathia, and hydrocephaly) and in rabbits at 90 mg/kg/day (including cardiovascular and renal anomalies, such as ectopia cordis and ectopic kidneys, and diaphragmatic and umbilical hernia), in the absence of maternal toxicity. The systemic exposure at these levels is approximately equivalent to or less than 0.5 times the clinical exposure at the recommended clinical dose of 2 g/day for renal transplant patients and approximately 0.3 times the clinical exposure at the recommended clinical dose of 3 g/day for cardiac transplant patients (see section 4.6).</p><p>The haematopoietic and lymphoid systems were the primary organs affected in toxicology studies conducted with mycophenolate mofetil in the rat, mouse, dog and monkey. These effects occurred at systemic exposure levels that are equivalent to or less than the clinical exposure at the recommended dose of 2 g/day for renal transplant recipients. Gastrointestinal effects were observed in the dog at systemic exposure levels equivalent to or less than the clinical exposure at the recommended dose. Gastrointestinal and renal effects consistent with dehydration were also observed in the monkey at the highest dose (systemic exposure levels equivalent to or greater than clinical exposure). The nonclinical toxicity profile of mycophenolate mofetil appears to be consistent with adverse events observed in human clinical trials, which now provide safety data of more relevance to the patient population (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp; Povidone<br />-&nbsp;&nbsp;&nbsp; Croscarmellose sodium<br />-&nbsp;&nbsp;&nbsp; Microcrystalline cellulose<br />-&nbsp;&nbsp;&nbsp; Magnesium stearate<br />-&nbsp;&nbsp;&nbsp; Opadry grey.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum blisters.</p><p>Pack size: 50 Film-coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03 September 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>